TY - JOUR T1 - Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer JF - Anticancer Research JO - Anticancer Res SP - 313 LP - 318 DO - 10.21873/anticanres.13113 VL - 39 IS - 1 AU - JU-HYUN KIM AU - YONG SIK YOON AU - JIN CHEON KIM AU - YONG-MAN KIM Y1 - 2019/01/01 UR - http://ar.iiarjournals.org/content/39/1/313.abstract N2 - Aim: To prospectively correlate clinical responses to second-line chemotherapy for recurrent epithelial ovarian cancer (EOC) with in vitro integrative tumor-response assay (ITRA) results. Patients and Methods: Forty-four patients with advanced EOC were enrolled from 2015-2017 at the Asan Medical Center, Seoul, Korea. ITRA comprised of two sequential histoculture drug response assays (HDRAs) of the tumor tissues. The first stage was HDRA with paclitaxel–carboplatin, paclitaxel, and carboplatin chemotherapy. The second stage was performed with surviving tumor cells from the first stage using topotecan, belotecan, gemcitabine, doxorubicin, ifosfamide, vinorelbine, and etoposide. Results: The median follow-up period was 23.35 (range=4-35.35) months. Eighteen patients (40.9%) completed the second-line chemotherapy, based on the ITRA results. The objective response rate was 38.9%. The clinical response rate was 50%; two patients (11.1%) had stable disease. The sensitivity of ITRA for predicting response was 85.7% (specificity=18.2%; accuracy=44.44%). Conclusion: ITRAs had acceptable applicability and may help choose second-line chemotherapy for patients with advanced EOC. ER -